Abstract: The present invention relates to a method of treating cranial fluid volume dysfunctions such as glaucoma in an individual, comprising administering compounds which effect an increase in cyclic GMP at the site of the dysfunction or at the site of synthesis or removal of the accumulating fluid. In particular, the method of treatment involves the topical use of hydralazine, non-organic nitrites or nitroglycerine, and the systematic use of hydralazine or non-organic nitrites.

Abstract: A method of controlling an invertebrate pest, comprising contacting the pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay is disclosed. Compositions comprising compounds capable of inhibiting the octopamine reuptake transporter include chloroethylphenylamines, aryl-1,4-dialkyl piperazines, tricyclic antidepressants, and cocaine derivatives. A process for inhibiting the feeding of an invertebrate pest comprising contacting said pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay, with the proviso that said agent is not cocaine. A process for delaying the maturation of a juvenile invertebrate by contacting it with an inhibitory amount of a phenylethanolamine reuptake transporter blocker is also disclosed.

Abstract: A pest-controlling composition which comprises:(A) a first compound capable of substantially inhibiting a phosphodiesterase enzyme (PDE) of said pest; and(B) a second compound having pest-dontrolling activity towards said pest, selected from the group consisting of(1) a substantial octopamine agonist toward an octopamine receptor present in said pest;(2) a compound directly and substantially stimulating the enzyme, adenylate cyclase; and(3) a cyclic adenosine monophosphate (cAMP) analogue.

Abstract: The invention is directed to azido-substituted octopamine agonists and the radiolabeled derivatives thereof. The invention also relates to past controlling compositions comprising the azido-substituted octopamine agonists of the invention.The invention also relates to methods of controlling invertebrate pests by bringing the pest into contact with an invertebrate pest-controlling composition of the invention and to an apparatus for controlling invertebrate pests utilizing the pest-controlling compositions of the invention. The pest-controlling compositions may be used alone or in conjunction with ultraviolet light.The invention also relates to methods for the isolation of octopamine receptor proteins utilizing the radiolabeled azido-substituted octopamine agonists of the invention.

Abstract: The use of xanthine derivatives having the general formula: ##STR1## as pesticidal and pestistatic agents is disclosed, as well as pesticidal and pestistatic compositions containing same.

Abstract: The invention relates to an invertebrate pest controlling composition comprising an invertebrate pest-controlling amount of a non-formamidine octopamine against having substantial activity toward an octopamine receptor present in an invertebrate pest and a pesticidally inert carrier.

Abstract: A method of controlling a pest which comprises bringing into contact with the pest a pest-controlling amount of an agent selected from the group consisting of(1) a non-formamidine -p-octopamine agonist having substantial activity toward an octopamine receptor present in the pest;(2) a compound directly and substantially stimulating the enzyme, adenylate cyclase; and(3) a cyclic adenosine monophosphate (cAMP) analogue.

Abstract: A method of decreasing the intraocular pressure in the eye of an animal which comprises administering to the animal an intraocular pressure decreasing amount of a beta.sub.2 adrenergic receptor antagonist having a .beta..sub.2 /.beta..sub.1 potency ratio of at least 10. The method is particularly useful for the treatment of glaucoma in humans.

Abstract: A method of decreasing the intraocular pressure in the eye of an animal which comprises administering to the animal an intraocular pressure decreasing amount of a beta.sub.2 adrenergic receptor antagonist having a .beta..sub.2 /.beta..sub.1 potency ratio of at least 25. The method is particularly useful for the treatment of glaucoma in humans.